Bone-targeting metal organic framework medicine loaded with traditional Chinese medicine component composition and preparation method of bone-targeting metal organic framework medicine

By modifying zoledronic acid on UiO-66-NH2 and combining astragalus membranacetin, icariin and panaxanthin R1, bone-targeting metal organic skeleton drugs were prepared, which solved the existing drugs in the treatment of postmenopausal bones. The safety and side effects of quasioporosis have achieved targeted delivery and promotion of bone, significantly improving the therapeutic effect.

CN119074951APending Publication Date: 2024-12-06GUANGDONG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012865.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing drugs used to treat postmenopausal osteoporosis have safety and side effects, and a safer and more effective treatment method is urgently needed.

Method used

Using bone-targeting metal organic skeleton drug loaded with Chinese medicine component composition, UiO-66-NH2 is chemically modified by using zoledronic acid as a targeting group, and astragaloside, icariin and three Heptasaponin R1 is combined with it as a composition of active ingredient in traditional Chinese medicine to prepare Drug@UiO-66-ZOL to achieve targeted bone delivery.

Benefits of technology

This drug has a promoting effect on osteoporotic cells within a certain concentration range, reducing the toxic side effects of the drug, significantly improving bone differentiation and mineralization capabilities, and exhibiting bone targeting in vitro and in vitro, improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074951A_ABST
    Figure CN119074951A_ABST
Patent Text Reader

Abstract

The invention discloses a bone targeting metal organic framework medicine loaded with a traditional Chinese medicine component composition and a preparation method thereof, and the medicine comprises a bone targeting metal organic framework medicine carrier and a traditional Chinese medicine active component composition loaded on the bone targeting metal organic framework medicine carrier, the traditional Chinese medicine active ingredient composition is a composition formed by compatibility of astragaloside, icariin and notoginsenoside R1. The preparation method comprises the following steps: (S1) preparing the Dyg-coated UiO-66-NH2; (S2) preparing the Dyg-coated UiO-66-NH2; s2, preparing activated zoledronic acid; and S3, preparing the Dyg (at) UiO-66-ZOL. The bone targeting metal organic framework medicine loaded with the traditional Chinese medicine component composition is good in biocompatibility, has a promoting effect on cell relative activity of PMOP OB, reduces toxic and side effects caused by too high medicine concentration, has a promoting effect on differentiation and mineralization of PMOP OB, and has a bone targeting effect in vivo and in vitro.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a bone-targeted metal organic framework drug loaded with a traditional Chinese medicine component composition and a preparation method thereof. Background Art

[0002] Postmenopausal osteoporosis (PMOP) is a bone metabolic disease that women are prone to after menopause. More than 30% of women suffer from systemic bone pain and bone microstructural changes due to osteoporosis after menopause. The reason is that insufficient estrogen secretion in the body leads to poor calcium absorption and bone loss. The disease is insidious, and the balance of bone homeostasis is destroyed, resulting in a decrease in the load-bearing capacity of bones and brittle fractures. Fractures caused by osteoporosis and its complications have a high disability rate and mortality rate. It is predicted that the medical expenses incurred in 2050 will reach 163 billion yuan. In recent years, research on PMOP has continued to develop and progress. How to prevent and treat PMOP is one of the issues that modern medicine cannot ignore.

[0003] There are many drugs for the treatment of osteoporosis on the market, including bone nutritional supplements (alfacalcidol, calcium carbonate), bone resorption inhibitors (alendronate, zoledronic acid), bone formation promoting drugs, etc. However, long-term use of such drugs may lead to an increase in the incidence of various diseases. There is an urgent need to develop safer and more effective methods to treat osteoporosis. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a bone-targeted metal organic framework drug loaded with a Chinese medicinal component composition and a preparation method thereof in view of the deficiencies in the above-mentioned prior art.

[0005] In order to solve the above technical problems, the technical solution of the present invention is:

[0006] A bone-targeted metal organic framework drug carrier, wherein the bone-targeted metal organic framework drug carrier uses zoledronic acid as a targeting group to chemically modify the surface of a metal organic framework material, wherein the metal organic framework material is UiO-66-NH 2 .

[0007] The bone-targeted metal organic framework drug carrier as described above is used to prepare a drug for treating postmenopausal osteoporosis.

[0008] A bone-targeted metal-organic framework drug loaded with a Chinese medicine component composition, comprising the bone-targeted metal-organic framework drug carrier as described above and a Chinese medicine active component composition loaded on the bone-targeted metal-organic framework drug carrier, wherein the Chinese medicine active component composition is a composition of astragaloside IV, icariin and notoginsenoside R1.

[0009] As a preferred embodiment, the mass ratio of astragaloside IV, icariin and notoginsenoside R1 is 3:1:3.

[0010] A method for preparing a bone-targeted metal-organic framework drug loaded with a Chinese medicinal composition as described above comprises the following steps:

[0011] S1. Preparation of Drug@UiO-66-NH 2 :UiO-66-NH 2 Dissolve in solvent A, add astragaloside IV, icariin and notoginseng saponin R1 and stir to react to obtain Drug@UiO-66-NH 2 ;

[0012] S2. preparing activated zoledronic acid: dissolving zoledronic acid in solvent B, adding triethylamine and N,N'-carbonyldiimidazole, and reacting with stirring under a nitrogen atmosphere to obtain activated zoledronic acid;

[0013] S3, preparation of Drug@UiO-66-ZOL: Drug@UiO-66-NH obtained in S1 2 The activated zoledronic acid prepared from S2 was dissolved in solvent C, triethylamine was added, and the mixture was stirred under a nitrogen atmosphere to obtain Drug@UiO-66-ZOL.

[0014] As a preferred embodiment, the solvent A is methanol; the mass ratio of astragaloside IV, icariin and notoginsenoside R1 is 3:1:3.

[0015] As a preferred embodiment, the solvent B is dimethylformamide.

[0016] As a preferred embodiment, the mass ratio of the zoledronic acid, the triethylamine and the N,N'-carbonyldiimidazole is 50:2:45.

[0017] As a preferred embodiment, the solvent C is dimethyl sulfoxide.

[0018] As a preferred embodiment, the Drug@UiO-66-NH 2 The mass ratio of the activated zoledronic acid and the triethylamine is 250:113:5.

[0019] For drug treatment of postmenopausal osteoporosis, in order to improve the efficacy and avoid the serious side effects caused by conventional drug treatment, the drug can usually be modified by targeting, concentrating the drug in the bones and reducing the drug concentration in the liver and spleen. In addition to its significant bone targeting, bisphosphonates also have excellent stability. When coupled with various compounds, they will not produce structural changes. They are currently widely used bone-targeted ligands. Zoledronic acid (ZOL) belongs to the third generation of bisphosphonates. ZOL has a strong affinity with bone tissue. It can be used as a bone-targeting molecule to modify the surface of the material to prepare bone-targeted nanomaterials.

[0020] Metal-organic frameworks (MOFs) are a new type of biomaterials that have great potential for development in biomedicine and drug delivery due to their special porous structures. These MOFs consist of coordination between metal ions / clusters and organic ligands / linkers, and have advantages such as large specific surface area, high porosity, good stability, high surface pH, excellent biocompatibility and biodegradability. UiO-66, as one of the most attractive MOFs, has been shown to promote osteogenesis in addition to its typical advantages observed in most MOFs, such as large specific surface area, high porosity and good biocompatibility. Zirconium (Zr), as the metal ion in UiO-66, can induce osteogenesis by stimulating the attachment, proliferation and differentiation of osteoblasts. Related studies have shown that amino-rich (-NH 2 ) is conducive to the osteogenic differentiation of mesenchymal stem cells, which means that the surface of -NH 2 Modification of the material can regulate the adhesion of osteoblasts and promote osteoblast differentiation.

[0021] The beneficial effects of the present invention are as follows: the bone-targeted metal-organic framework drug loaded with the Chinese medicinal ingredient composition has good biocompatibility, promotes the relative cell activity of PMOP OB within a certain concentration range, and can reduce the toxic side effects caused by excessive drug concentration; and the bone-targeted metal-organic framework drug loaded with the Chinese medicinal ingredient composition promotes the differentiation and mineralization of PMOP OB; the bone-targeted metal-organic framework drug loaded with the Chinese medicinal ingredient composition has a bone-targeting effect both in vivo and in vitro. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 UiO-66-NH 2 Theoretical XRD patterns and self-prepared UiO-66-NH 2 Sample XRD pattern;

[0023] Figure 2 UiO-66-NH 2 、Drug@UiO-66-NH 2and XRD patterns of Drug@UiO-66-ZOL;

[0024] Figure 3 UiO-66-NH 2 (A) Drug@UiO-66-NH 2 (B) and SEM images of Drug@UiO-66-ZOL (C);

[0025] Figure 4 UiO-66-NH 2 (A) Drug@UiO-66-NH 2 (B) and TEM images of Drug@UiO-66-ZOL (C);

[0026] Figure 5 UiO-66-NH 2 (A) Drug@UiO-66-NH 2 (B) and particle size analysis of Drug@UiO-66-ZOL (C);

[0027] Figure 6 UiO-66-NH 2 Nitrogen adsorption-desorption curve spectrum;

[0028] Figure 7 Drug@UiO-66-NH 2 Nitrogen adsorption-desorption curve spectrum;

[0029] Figure 8 UiO-66-NH 2 FT-IR spectrum of

[0030] Fig. 9 UiO-66-NH 2 、Drug@UiO-66-NH 2 , FT-IR spectra of astragaloside IV, icariin and notoginsenoside R1;

[0031] Fig.10 Drug@UiO-66-NH 2 , FT-IR spectra of Drug@UiO-66-ZOL and ZOL;

[0032] Fig.11 is the HPLC standard curve of astragaloside IV;

[0033] Fig.12 is the HPLC standard curve of icariin;

[0034] Fig.13 is the HPLC standard curve of notoginsenoside R1;

[0035] Fig.14 RhB-Drug@UiO-66-NH 2 The uptake of PMOP OB under the action;

[0036] Fig.15 The uptake of PMOP OB under the action of RhB-Drug@UiO-66-ZOL;

[0037] Fig.16 UiO-66-NH 2 Relative activity of PMOP OB after 48 h of action with UiO-66-ZOL;

[0038] Fig.17 Drug and Drug@UiO-66-NH at different concentrations 2 Relative activity of PMOPOB after 48h of treatment with Drug@UiO-66-ZOL;

[0039] Fig.18 Drug, Drug@UiO-66-NH 2 ALP staining results in PMOP OB after 48 h of treatment with Drug@UiO-66-ZOL;

[0040] Fig.19 Drug, Drug@UiO-66-NH 2 and Drug@UiO-66-ZOL for 48 h, the expression of ALP in PMOP OB;

[0041] Fig. 20 Drug, Drug@UiO-66-NH 2 ARS staining results of mineralized nodules produced in PMOP OB after 48h of treatment with Drug@UiO-66-ZOL;

[0042] Fig.21 Drug, Drug@UiO-66-NH 2 Changes in relative calcium ion concentration in PMOP OB after 48 h of treatment with Drug@UiO-66-ZOL;

[0043] Fig. 22 RhB-Drug@UiO-66-NH 2 (A) Adsorption of RhB-Drug@UiO-66-ZOL (B) in hydroxyapatite;

[0044] Fig.23To use RhB-Drug@UiO-66-NH 2 RhB-Drug@UiO-66-ZOL and RhB-Drug@UiO-66-ZOL were injected into the rats through the tail vein. After 48 hours of administration, RhB-Drug@UiO-66-NH 2 (A) and distribution diagram of RhB-Drug@UiO-66-ZOL(B). DETAILED DESCRIPTION

[0045] The structural principle and working principle of the present invention are further described in detail below with reference to the accompanying drawings.

[0046] Example

[0047] Preparation of Drug@UiO-66-ZOL

[0048] S1. Preparation of Drug@UiO-66-NH 2 : Take a 50mL beaker and add 50mgUiO-66-NH 2 , add 30mL methanol, ultrasonically dissolve, and then add 60mg astragaloside IV, 60mg notoginseng saponin R1, and 20mg icariin. After ultrasonic dissolution, stick the sealing film and continue stirring at room temperature for 72h. After the reaction, collect the sample solution, centrifuge at 12000r / min for 5min, discard the supernatant, wash the bottom precipitate with methanol ultrasonically three times, centrifuge, discard the supernatant, place the bottom material in a -20℃ refrigerator and freeze for 2h, then take it out of the -20℃ refrigerator and quickly transfer it to a vacuum freeze dryer. After drying for 24h, collect the product to obtain Drug@UiO-66-NH 2 ;

[0049] S2, preparation of activated zoledronic acid: take a 100mL round-bottom flask, add 50mg zoledronic acid (ZOL), add 25mL dimethylformamide (DMF), after ultrasonic dissolution, add 2mL triethylamine, then add 45mg N, N'-carbonyldiimidazole (CDI) and quickly protect with nitrogen, place the round-bottom flask in a 60℃ oil bath and stir continuously for 24h. After the reaction is completed, collect the sample solution, centrifuge at 12000r / min for 5min, discard the supernatant, wash the bottom precipitate with acetonitrile ultrasonically three times, centrifuge, discard the supernatant, place the bottom material in a -20℃ refrigerator and freeze for 2h, take it out from the -20℃ refrigerator and quickly transfer it to a vacuum freeze dryer, collect the product after drying for 24h, and obtain activated zoledronic acid;

[0050] S3, preparation of Drug@UiO-66-ZOL: Take a 100 mL round-bottom flask and add 50 mg of Drug@UiO-66-NH prepared in S1 2, add 10mL dimethyl sulfoxide (DMSO), dissolve by ultrasound, add 22.6mg activated zoledronic acid prepared by S2, continue to dissolve by ultrasound, add 1mL triethylamine, and stir continuously for 12h under nitrogen protection. After the reaction, collect the sample solution, centrifuge at 12000r / min for 5min, discard the supernatant, freeze the bottom material in a -20℃ refrigerator for 2h, take it out from the -20℃ refrigerator and quickly transfer it to a vacuum freeze dryer, collect the product after drying for 24h, and obtain Drug@UiO-66-ZOL.

[0051] Comparative Example 1

[0052] Preparation of UiO-66-NH 2

[0053] Take a 100mL beaker and add 420mg zirconium tetrachloride (ZrCl 4 ), add 60 mL of dimethylformamide (DMF), dissolve by ultrasonication to obtain solution A; take another 50 mL beaker, add 1100 mg of 2-aminoterephthalic acid (NH 2 -BDC), add 20mL DMF, and dissolve it by ultrasonic to obtain liquid B; take 20 20mL reaction bottles, take 3mL A liquid and 1mL B liquid into the reaction bottle respectively, add 100μL acetic acid to each bottle, cover the lid, and place it in an oven at 96℃ for 6h. After the reaction is completed, the sample solution is transferred to a centrifuge tube, centrifuged at 12000r / min for 5min, the supernatant is discarded, the bottom precipitate is ultrasonically washed twice with DMF, and then ultrasonically washed once with methanol, centrifuged, the supernatant is discarded, the bottom material is placed in a -20℃ refrigerator and frozen for 2h, then taken out from the -20℃ refrigerator and quickly transferred to a vacuum freeze dryer, and the product is collected after drying for 24h to obtain UiO-66-NH 2 .

[0054] Comparative Example 2

[0055] Preparation of RhB-Drug@UiO-66-NH 2

[0056] Take a 20 mL reaction bottle and add 2 mg of Drug@UiO-66-NH prepared in Example S1 2 , add 4 mL of ultrapure water, ultrasonically dissolve, add 4 mg of RhB, continue ultrasonically dissolve, and continue ultrasonication for 2 hours under light-proof conditions. After the reaction is completed, collect the sample solution, centrifuge at 12000 r / min for 5 minutes, discard the supernatant, and wash the bottom precipitate with ultrapure water ultrasonically three times, centrifuge, discard the supernatant, and freeze the bottom material in a -20℃ refrigerator for 2 hours, then take it out of the -20℃ refrigerator and quickly transfer it to a vacuum freeze dryer. After drying for 24 hours, collect the product to obtain RhB-Drug@UiO-66-NH2 .

[0057] Comparative Example 3

[0058] Preparation of RhB-Drug@UiO-66-ZOL

[0059] Take a 20mL reaction bottle, add 2mg of Drug@UiO-66-ZOL prepared in the example, add 4mL of ultrapure water, add 4mgRhB after ultrasonic dissolution, continue ultrasonic dissolution, and continue ultrasonication for 2h under light-proof conditions. After the reaction is completed, collect the sample solution, centrifuge at 12000r / min for 5min, discard the supernatant, wash the bottom precipitate with ultrapure water ultrasonically three times, centrifuge, discard the supernatant, place the bottom material in a -20℃ refrigerator and freeze for 2h, then take it out of the -20℃ refrigerator and quickly transfer it to a vacuum freeze dryer, collect the product after drying for 24h, and obtain RhB-Drug@UiO-66-ZOL.

[0060] Test Example 1

[0061] X-ray diffraction experiments

[0062] The UiO-66-NH prepared in the comparative example was analyzed by X-ray diffraction analyzer. 2 Tested and used with UiO-66-NH 2 Compared with the theoretical XRD pattern of Figure 1 shown.

[0063] Depend on Figure 1 It can be seen that UiO-66-NH 2 The theoretical XRD pattern of UiO-66-NH prepared in the comparative example 2 The XRD patterns of the two samples showed that the peak information of the two samples was basically consistent, indicating that the UiO-66-NH 2 The structure is correct.

[0064] Test Example 2

[0065] X-ray diffraction experiments

[0066] The UiO-66-NH prepared in the comparative example was analyzed by X-ray diffraction analyzer. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2 The Drug@UiO-66-ZOL prepared in the embodiment was tested, and the results were as follows Figure 2 shown.

[0067] Depend on Figure 2 It can be seen that Drug@UiO-66-NH 2The diffraction patterns of Drug@UiO-66-ZOL are good, which is similar to that of UiO-66-NH 2 High matching degree indicates that UiO-66-NH 2 After loading the active ingredient composition of traditional Chinese medicine and modifying ZOL, the crystal structure will not be destroyed.

[0068] Test Example 3

[0069] Scanning electron microscopy experiment

[0070] The UiO-66-NH prepared by the comparative example was observed by scanning electron microscope. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2 The Drug@UiO-66-ZOL prepared in the embodiment was tested, and the test results are as follows Figure 3 shown.

[0071] Depend on Figure 3 It can be seen that UiO-66-NH 2 、Drug@UiO-66-NH 2 and Drug@UiO-66-ZOL have good dispersibility, uniform distribution, and regular shape.

[0072] Test Example 4

[0073] Transmission electron microscopy experiment

[0074] The UiO-66-NH prepared in the comparative example was observed by transmission electron microscopy. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2 The Drug@UiO-66-ZOL prepared in the embodiment was tested, and the test results are as follows Figure 4 shown.

[0075] Depend on Figure 4 It can be seen that UiO-66-NH 2 、Drug@UiO-66-NH 2 and Drug@UiO-66-ZOL are spherical or cuboid in shape, and the particle size is about 100nm to 200nm.

[0076] Test Example 5

[0077] Particle size distribution experiment

[0078] The UiO-66-NH prepared in the comparative example was analyzed by laser particle size analyzer. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2The Drug@UiO-66-ZOL prepared in the embodiment was tested, and the test results are as follows Figure 5 shown.

[0079] Depend on Figure 5 It can be seen that UiO-66-NH 2 、Drug@UiO-66-NH 2 The average particle sizes of Drug@UiO-66-ZOL are 121.5nm, 125.5nm and 135.7nm, respectively.

[0080] Test Example 6

[0081] Nitrogen adsorption-desorption curve measurement

[0082] An appropriate amount of sample was placed under vacuum pretreatment at 90 °C for 5 h, and then the nitrogen adsorption-desorption curve was measured at 77 K using a specific surface area and pore size analyzer.

[0083] The sample is UiO-66-NH prepared in the comparative example. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2 , the results are as follows Figure 6 and Figure 7 shown.

[0084] Depend on Figure 5 It can be seen that UiO-66-NH 2 The nitrogen adsorption capacity is about 350 cm 3 / g, its specific surface area is 1180.6134m 2 / g, indicating that UiO-66-NH 2 Can be used to load the active ingredient composition of traditional Chinese medicine; Figure 6 It can be seen that Drug@UiO-66-NH 2 Nitrogen adsorption decreased to 200 cm 3 / g, the specific surface area is reduced to 682.5096m 2 / g, indicating that UiO-66-NH 2 After loading the active ingredient composition of traditional Chinese medicine, the pores are occupied.

[0085] Test Example 7

[0086] Fourier transform infrared spectroscopy

[0087] Weigh an appropriate amount of sample and potassium bromide in a ratio of 1:1000 and grind in an agate mortar. After drying, press the sample into a tablet and use a Fourier transform infrared spectrometer to scan the sample for infrared spectrum. The measurement range is 400cm -1 ~4000cm -1 .

[0088] The sample is UiO-66-NH prepared in the comparative example. 2 Drug@UiO-66-NH obtained by step S1 in the embodiment 2 , commercially available astragaloside IV, commercially available icariin, commercially available notoginseng saponin R1, Drug@UiO-66-ZOL prepared in Example 1, and commercially available zoledronic acid. The results are as follows Figure 8 , Fig. 9 and Fig.10 shown.

[0089] Depend on Figure 8 It is known that NH 2 -BDC contains free carboxylate, but the corresponding carboxylic acid characteristic peak is not shown in the spectrum, indicating that it has completed the reaction with Zr 4+ The coordination of the metal organic framework UiO-66-NH 2 Successfully prepared by Fig. 9 It can be seen that at about 840cm -1 Department of Drug@UiO-66-NH 2 The spectrum shows the same characteristic peak as that of astragaloside IV, icariin and notoginseng saponin R1, and this characteristic peak is 2 Not shown in the spectrum, indicating that Drug@UiO-66-NH 2 A composition loaded with active ingredients of traditional Chinese medicine; Fig.10 It can be seen that, with Drug@UiO-66-NH 2 Compared with the spectrum of Drug@UiO-66-ZOL, the spectrum of Drug@UiO-66-ZOL is around 600cm -1 There is an additional phosphoric acid characteristic peak at the position, which is very obvious in the ZOL spectrum, indicating that ZOL has been successfully modified to the skeleton.

[0090] Test Case 8

[0091] Determination of loading rate of bone-targeted metal-organic framework drugs loaded with traditional Chinese medicine composition

[0092] (1) Draw a standard curve

[0093] Ultrapure water (A) and acetonitrile (B) were used as mobile phases, and the gradient elution conditions were shown in Table 1. The terminal absorption peak was detected at a wavelength of 203 nm. Take a 50 mL beaker, add 10 mg of astragaloside IV standard, 1.25 mg of icariin standard, 5 mg of notoginseng saponin R1 standard, add 10 mL of chromatographic methanol, and ultrasonically dissolve to obtain standard products with drug concentrations of 1000 μg / mL for astragaloside IV, 125 μg / mL for icariin, and 1500 μg / mL for notoginseng saponin R, and dilute them in a gradient ratio of 1:3:5:8:10. Use a microporous filter membrane with a pore size of 0.22 μm to filter the mixed standard for later use. First, the peak retention time of astragaloside IV, icariin, and notoginsenoside R1 was detected by high performance liquid chromatography, and the corresponding relationship between each peak retention time and each drug under the elution condition was determined in turn. Then, the mixed standard solution was tested, the peak area was counted, and the standard curve was drawn. The results are as follows: Fig.11 , Fig.12 and Fig.13 As shown;

[0094] Table 1 Gradient elution conditions for determining loading rate by HPLC

[0095] Ultrapure water (A) (%) Acetonitrile (B) (%) 0~5min 80 20 5~12min 80~62 20~38 12~27min 62 38

[0096] (2) Determination of loading rate of active ingredient composition of traditional Chinese medicine

[0097] Accurately weigh 5mgDrug@UiO-66-NH 2 Powder, add 20mL PBS, ultrasonicate for 60min, and make Drug@UiO-66-NH 2 After the loaded active ingredient composition of traditional Chinese medicine is completely released, the sample solution is transferred to a centrifuge tube, centrifuged at 12000r / min for 3min, the supernatant is collected, filtered and transferred to a sample injection bottle for testing on the machine. The loading rate calculation method is as follows:

[0098]

[0099] The results are shown in Table 2.

[0100] Table 2 Drug@UiO-66-NH 2 Drug loading rate of Drug@UiO-66-ZOL (%)

[0101]

[0102] Depend on Fig.11 , Fig.12 and Fig.13As shown in Table 2, the standard curve regression coefficients of astragaloside IV, icariin and notoginseng saponin R1 are 0.9996, 0.9993 and 0.9997, respectively, indicating that under this elution condition, the peak area and drug concentration of these three drugs maintain an excellent linear relationship; as shown in Table 2, Drug@UiO-66-NH 2 The loading rates of astragaloside IV, icariin and notoginsenoside R1 were 3.74%, 2.51% and 3.83% respectively; the loading rates of astragaloside IV, icariin and notoginsenoside R1 in Drug@UiO-66-ZOL were 2.67%, 2.46% and 2.96% respectively. After targeted modification of ZOL, the loading rates of the three drugs were slightly affected.

[0103] Primary PMOP OB culture

[0104] Primary PMOP OBs were extracted from the skull of postmenopausal osteoporotic rats. PMOP OBs were cultured in a culture medium containing 15% serum, and subcultured or plated when the cell density was about 80%.

[0105] Test Example 9

[0106] Effect of PMOP OB on the uptake of bone-targeted metal-organic framework drugs loaded with traditional Chinese medicine components

[0107] Use 24-well plates for cell experiments. Count the number of cells in the culture flask using a cell counting plate. 4 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2 The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded and the RhB-Drug@UiO-66-NH prepared in Comparative Example 2 was added. 2 The RhB-Drug@UiO-66-ZOL prepared in Comparative Example 3 was added to the culture medium, and the drug concentration was adjusted to 100 μg / mL. According to the duration of the uptake action, the cells were grouped into: 2h group, 4h group, 6h group, and 8h group, with two replicate wells in each group. After the corresponding uptake action time, the old culture medium in the well plate was discarded, 500 μL PBS was added to each well for washing, PBS was discarded, and the washing was repeated three times. After adding 500 μL 70% ethanol to fix the cells for 15 minutes, 500 μL PBS was added for washing three times, PBS was discarded, 200 μL Hoechst nuclear stain was added, and the stain was discarded after staining for 10 minutes. After adding 500 μL PBS and washing three times, the effect of PMOP OB on RhB-Drug@UiO-66-NH 2 The results of the uptake of RhB-Drug@UiO-66-ZOL are shown in Fig.14 and Fig.15 .

[0108] Depend on Fig.14 and Fig.15 It can be seen that the blue fluorescence is the cell nucleus of PMOP OB after nuclear staining, and the red fluorescence is RhB-Drug@UiO-66-NH 2 Or RhB-Drug@UiO-66-ZOL. After 2 hours of action, only a small amount of red fluorescence was in the cytoplasm, and the PMOP OB uptake was small at this time. As the action time prolonged, PMOP OB took RhB-Drug@UiO-66-NH 2 Or the uptake of RhB-Drug@UiO-66-ZOL increased, showing stronger red fluorescence after 8 h of action.

[0109] Test Example 10

[0110] UiO-66-NH 2 Effects of UiO-66-ZOL and PMOP OB activity

[0111] Use 96-well plates for cell experiments. Count the number of cells in the culture flask using a cell counting plate. 3 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2 The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded and the drugs were divided into groups. Each group had three replicate wells, and each well had 100 μL of drug-containing culture medium. The cells were divided into: blank group, UiO-66-NH 2 The concentration gradient of the UiO-66-ZOL group was 5 μg / mL to 120 μg / mL.

[0112] 48 hours after administration, discard the old culture medium, add 100 μL of culture medium containing 10% CCK8 to each well, cover with tin foil to avoid light, and incubate at 37°C, CO 2 After incubation in an incubator with a concentration of 5% for 2 hours, the absorbance was measured at a wavelength of 450nm and the relative activity of the cells was calculated. The results are as follows Fig.16 shown.

[0113] Depend on Fig.16 It can be seen that within the concentration range of 5 μg / mL to 120 μg / mL, the relative activity of PMOP OB is greater than 90%, and UiO-66-NH 2 and UiO-66-ZOL had little effect on the relative activity of PMOP OB.

[0114] Test Example 11

[0115] Effects of bone-targeted metal-organic framework drugs loaded with traditional Chinese medicine components on the OB activity of PMOP

[0116] Use 96-well plates for cell experiments. Count the number of cells in the culture flask using a cell counting plate. 3 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2 The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded and the drugs were divided into groups. Each group had three replicate wells, and each well had 100 μL of drug-containing culture medium. The cells were divided into: Chinese medicine active ingredient composition group (Drug group), Drug@UiO-66-NH 2 group and Drug@UiO-66-ZOL group, the concentration gradient was: 5μg / mL~120μg / mL.

[0117] 48 hours after administration, discard the old culture medium, add 100 μL of culture medium containing 10% CCK8 to each well, cover with tin foil to avoid light, and incubate at 37°C, CO 2 After incubation in an incubator with a concentration of 5% for 2 hours, the absorbance was measured at a wavelength of 450nm and the relative activity of the cells was calculated. The results are as follows Fig.17 shown.

[0118] Depend on Fig.17 It can be seen that the relative activity of PMOP OB was promoted at low concentrations and inhibited at high concentrations. 2 The drug@UiO-66-NH group and the drug@UiO-66-ZOL group had a significant effect on promoting PMOP OB, and the difference was statistically significant compared with the drug group (*P<0.05). 2 The inhibitory effects of the UiO-66-ZOL group and the Drug@UiO-66-ZOL group on PMOP OB were weakened, and the differences were statistically significant compared with the Drug group (**P<0.01, ***P<0.001).

[0119] Test Example 12

[0120] Alkaline phosphatase staining experiment

[0121] Use 24-well plates for cell experiments. Count the number of cells in the culture flask using a cell counting plate. 4 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded and the drugs were divided into groups. Each group had three replicate wells, and each well had 500 μL of drug-containing culture medium. The cells were divided into: Control group, Drug group, Drug@UiO-66-NH 2 group and Drug@UiO-66-ZOL group.

[0122] 48 hours after administration, discard the old culture medium, add 500 μL PBS to each well for washing, discard PBS, wash three times repeatedly, add 500 μL 70% ethanol to fix the cells, discard 70% ethanol after fixation for 15 minutes, add 500 μL PBS to wash three times, discard PBS, add 500 μL BCIP / NBT staining working solution, stain in the dark for 30 minutes, discard the staining agent, add 500 μL PBS to wash three times repeatedly, discard PBS, air dry naturally, and observe in a live cell imager. The results are as follows Fig.18 shown.

[0123] Depend on Fig.18 It can be seen that compared with the Control group, the Drug group and Drug@UiO-66-NH 2 The staining color in the group and Drug@UiO-66-ZOL group was darker and the color area was larger.

[0124] Test Example 13

[0125] Quantitative detection of alkaline phosphatase

[0126] Use a 6-well plate for cell experiments, count the number of cells in the culture flask using a cell counting plate, and plate PMOPOB at 2×10 5 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2 The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded and the drugs were divided into groups. Each group had three replicate wells, and each well had 2 mL of drug-containing culture medium. The cells were divided into: Control group, Drug group, Drug@UiO-66-NH 2 group and Drug@UiO-66-ZOL group.

[0127] After incubation for 48 hours after administration, the culture plate was placed on ice, the old culture medium in the well plate was discarded, 500 μL PBS was added to each well for washing, PBS was discarded, and after repeated washing three times, 200 μL cell lysis solution was added, and the lysis solution was blown to produce foam covering the bottom of the well plate. Lysis was continued on ice for 30 minutes, during which time the lysis solution was continuously blown to keep the lysis solution covering the bottom of the well plate. After the lysis was completed, the lysate was collected and the supernatant was preserved by centrifugation.

[0128] Use the BCA kit to detect the protein concentration. Set up three replicate wells for each group. Add 2μL of the supernatant of each group to each well. Add 18μL PBS to dilute it 10 times, then add 200μL BCA working solution, set the oven temperature to 37°C, place it in the oven to react for 1 hour, measure the absorbance at a wavelength of 405nm, and calculate the protein concentration of each group. According to the protein concentration results of each group, use PBS to dilute it to the same concentration. After preparing the sample solution of the same concentration, use a 96-well plate, set three replicate wells for each group of sample solution, add 30μL of the diluted sample solution of each group to each well, add 20μL detection buffer, and then add 50μL colorimetric substrate. Set the oven temperature to 37°C, place it in the oven to react for 30 minutes, add the stop solution, measure the absorbance at a wavelength of 405nm, and calculate the ALP expression level of each group of samples. The results are as follows. Fig.19 shown.

[0129] Depend on Fig.19 It can be seen that compared with the Control group, the Drug group and Drug@UiO-66-NH 2 The expression of ALP in the Drug@UiO-66-ZOL group and the Drug@UiO-66-ZOL group was significantly increased, and the difference was statistically significant (****P<0.0001).

[0130] Test Case 14

[0131] Alizarin Red S staining experiment

[0132] Use 24-well plates for cell experiments. Count the number of cells in the culture flask using a cell counting plate. 4 The cells were inoculated at a density of 100 cells / well and the cell culture incubator was set at 37°C with CO 2 The concentration was 5%. After incubation for 24 hours until the cells attached to the wall, the old culture medium in the well plate was discarded, and the drugs were divided into groups. Each group had three replicate wells, and each well had 500 μL of drug-containing culture medium. Half of the medium was replaced every two days. The cells were divided into: Control group, Drug group, Drug@UiO-66-NH 2 group and Drug@UiO-66-ZOL group.

[0133] When the cells were cultured for 30 days, the old culture medium was discarded, 500 μL PBS was added to each well for washing, PBS was discarded, and the cells were washed three times repeatedly. Then, 500 μL 70% ethanol was added to fix the cells. After fixation for 15 min, 70% ethanol was discarded. Then, 500 μL PBS was added to wash three times. PBS was discarded, 500 μL Alizarin Red S staining solution was added, and the cells were stained in the dark for 30 min, and the staining solution was discarded. Then, 500 μL double distilled water was added to wash three times repeatedly, and the double distilled water was discarded. The cells were naturally air-dried and observed using a live cell imaging instrument. The results are shown in FIG. Fig. 20 shown.

[0134] Depend on Fig. 20 It can be seen that compared with the Control group, the Drug group and Drug@UiO-66-NH 2 The ARS staining area in the group and Drug@UiO-66-ZOL group was larger, and the number of mineralized nodules was greater.

[0135] Test Example 15

[0136] Calcium ion concentration detection

[0137] After the cells in each group in (1) were stained with Alizarin Red S and observed under a microscope, 500 μL of 10% cetylpyridinium chloride solution was added to each well, and the wells were placed on a shaker and continuously shaken for 30 min. After the mineralized nodules were completely dissolved, 100 μL of the solution after the mineralized nodules were dissolved was added to each well of a 96-well plate with three replicate wells for each group of solutions. The absorbance was measured at a wavelength of 562 nm, and the relative calcium ion concentration was calculated. The results are as follows: Fig.21 shown.

[0138] Depend on Fig.21 It can be seen that compared with the Control group, the Drug group and Drug@UiO-66-NH 2 The relative calcium ion concentration in the drug group and Drug@UiO-66-ZOL group was significantly increased, and the difference was statistically significant (***P<0.001, ****P<0.0001).

[0139] The statistical analysis used in the above test examples 11, 13 and 15 was performed using GraphPad Prism 9.0.0 statistical software. The values ​​were expressed as means. One-way ANOVA was used for comparison between multiple groups. If the differences were statistically significant, multiple t-tests were used for pairwise comparisons between groups, with a test level of α = 0.05.

[0140] Test Case 16

[0141] In vitro bone targeting assay

[0142] Take two 20 mL reaction bottles and add 5 mg of RhB-Drug@UiO-66-NH prepared in Comparative Example 2 to each bottle. 2 and 5 mg of RhB-Drug@UiO-66-ZOL prepared in Comparative Example 3, each was added with 10 mL of ultrapure water, and after ultrasonic dissolution, 10 mg of hydroxyapatite powder was added, and ultrasonic dissolution was continued, and stirred for 3 h at room temperature in the dark. After the reaction was completed, the sample solution was collected, centrifuged at 12000 r / min for 5 min, the supernatant was discarded, the bottom precipitate was ultrasonically washed three times with ultrapure water, and then continued to be dissolved with ultrapure water to obtain a hydroxyapatite suspension, and the suspension was aspirated and dropped onto a glass slide, and RhB-Drug@UiO-66-NH was observed under a microscope.2 and the adsorption of RhB-Drug@UiO-66-ZOL in hydroxyapatite. Fig. 22 shown.

[0143] Depend on Fig. 22 It can be seen that RhB-Drug@UiO-66-NH 2 In comparison, RhB-Drug@UiO-66-ZOL showed stronger red fluorescence and stronger adsorption in hydroxyapatite, confirming that the bone-targeted metal-organic framework drug loaded with the Chinese medicine component composition has a certain bone-targeting effect in vitro.

[0144] Test Case 17

[0145] In vivo bone targeting experiments

[0146] Eight 12-week-old female nulliparous SD rats were randomly divided into two groups according to their body weight: RhB-Drug@UiO-66-NH 2 After dissolving the drugs in each group with physiological saline, the drugs were filtered using a microporous filter membrane, and 1 mL of the drug (RhB-Drug@UiO-66-NH 2 The drug used in the group was RhB-Drug@UiO-66-NH prepared in Comparative Example 2. 2 The drug used in the RhB-Drug@UiO-66-ZOL group was the RhB-Drug@UiO-66-ZOL solution prepared in Comparative Example 3, and the injection dose was 5 mg / kg. 48 hours after the tail vein injection, the whole body of the rats in each group was photographed and observed using an animal in vivo imaging device. The results are as follows Fig.23 shown.

[0147] Depend on Fig.23 It can be seen that RhB-Drug@UiO-66-NH 2 Compared with the control group, the lower limbs and spine of the rats in the RhB-Drug@UiO-66-ZOL group showed stronger fluorescence, indicating that the drug can accumulate in the lower limbs and spine of the rats, confirming that the bone-targeted metal-organic framework drug loaded with the Chinese medicine composition has a certain bone-targeting effect in rats.

[0148] The above description is only a preferred embodiment of the present invention. Any slight modification, equivalent changes and modifications made to the above embodiments according to the technical solution of the present invention are within the scope of the technical solution of the present invention.

Claims

1. A bone-targeted metal-organic framework drug carrier, It is characterized in that The bone-targeted metal organic framework drug carrier uses zoledronic acid as a targeting group to chemically modify the surface of the metal organic framework material. The metal organic framework material is UiO-66-NH 2 .

2. A bone-targeted metal-organic framework drug carrier as claimed in claim 1 for use in preparing a drug for treating postmenopausal osteoporosis.

3. A bone-targeted metal-organic framework drug loaded with a composition of traditional Chinese medicine ingredients, It is characterized in that It comprises the bone-targeted metal-organic framework drug carrier as claimed in claim 1 and a composition of active ingredients of traditional Chinese medicine loaded on the bone-targeted metal-organic framework drug carrier, wherein the composition of active ingredients of traditional Chinese medicine is a composition of astragaloside IV, icariin and notoginseng saponin R1.

4. The bone-targeted metal organic framework drug loaded with a Chinese medicinal composition according to claim 3, It is characterized in that The mass ratio of astragaloside IV, icariin and notoginsenoside R1 is 3:1:

3.

5. A method for preparing a bone-targeted metal organic framework drug loaded with a Chinese medicinal composition as claimed in any one of claims 3 to 4, It is characterized in that The following steps are involved: S1. Preparation of Drug@UiO-66-NH 2 :UiO-66-NH 2 Dissolve in solvent A, add astragaloside IV, icariin and notoginseng saponin R1 and stir to react to obtain Drug@UiO-66-NH 2 ; S2. preparing activated zoledronic acid: dissolving zoledronic acid in solvent B, adding triethylamine and N,N'-carbonyldiimidazole, and reacting with stirring under a nitrogen atmosphere to obtain activated zoledronic acid; S3, preparation of Drug@UiO-66-ZOL: Drug@UiO-66-NH obtained in S1 2 The activated zoledronic acid prepared from S2 was dissolved in solvent C, triethylamine was added, and the mixture was stirred under a nitrogen atmosphere to obtain Drug@UiO-66-ZOL.

6. A method for preparing a bone-targeted metal organic framework drug loaded with a Chinese medicinal composition according to claim 5, It is characterized in that The solvent A is methanol; the mass ratio of astragaloside IV, icariin and notoginseng saponin R1 is 3:1:

3.

7. The method for preparing the bone-targeted metal organic framework drug loaded with the Chinese medicinal component composition according to claim 5, It is characterized in that The solvent B is dimethylformamide.

8. The method for preparing the bone-targeted metal organic framework drug loaded with the Chinese medicinal component composition according to claim 5, It is characterized in that The mass ratio of the zoledronic acid, the triethylamine and the N,N'-carbonyldiimidazole is 50:2:

45.

9. The method for preparing the bone-targeted metal organic framework drug loaded with the Chinese medicinal component composition according to claim 5, It is characterized in that The solvent C is dimethyl sulfoxide.

10. The method for preparing the bone-targeted metal organic framework drug loaded with the Chinese medicinal component composition according to claim 5, It is characterized in that The Drug@UiO-66-NH 2 The mass ratio of the activated zoledronic acid and the triethylamine is 250:113:5.